Genetic epidemiology of amyotrophic lateral sclerosis

Clinical Genetics

Volumn 63, Issue 2, 2003, Pages 83-101

  Majoor Krakauer, Danielle ^a   Willems, P J ^a   Hofman, A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amyotrophic lateral sclerosis; Epidemiology; Genetics

Indexed keywords

AGE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN NERVE CELL; CLASSIFICATION; DEMENTIA; DISEASE COURSE; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; FATALITY; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENE MUTATION; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; MOTONEURON; NERVE DEGENERATION; ONSET AGE; PENETRANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPINAL CORD NERVE CELL; TAUOPATHY;

AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; CAUSALITY; FEMALE; HUMANS; INHERITANCE PATTERNS; MALE; MUTATION; RISK FACTORS;

EID: 0042632880     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0009-9163.2002.00001.x     Document Type: Review

References (272)

1. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci 1994: 124: 96-107.
2. Swash M. An algorithm for ALS diagnosis and management. Neurology 1999: 53 (Suppl. 5): S58-S62.
3. Cote F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993: 73: 35-46.
4. Kennel PF, Finiels F, Revah F, Mallet J. Neuromuscular function impairment is not caused by motor neuron loss in FALS mice: an electromyographic study. Neuroreport 1996: 7: 1427-1431.
5. Riggs JE, Schochet SS. Rising mortality due to Parkinson's disease and amyotrophic lateral sclerosis: a manifestation of the competitive nature of human mortality. J Clin Epidemiol 1992: 45: 1007-1012.
6. Neilson S, Robinson I, Alperovitch A. Rising amyotrophic lateral sclerosis mortality in France 1968-90: increased life expectancy and inter-disease competition as an explanation. J Neurol 1994: 241: 448-455.
7. Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 1993: 12: 219-228.
8. Durrleman S, Alperovitch A. Increasing trend of ALS in France and elsewhere: are the changes real? Neurology 1989: 39: 768-773.
9. Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-88. Arch Neurol 1991: 48: 589-593.
10. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995-97: a population- based study. Neurology 1999: 52: 504-509.
11. Bobowick AR, Brody JA. Epidemiology of motor-neuron diseases. N Engl J Med 1973: 288: 1047-1055.
12. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995: 118: 707-719.
13. Cashman N, White C, Anderson F. Gender and presentation age in ALS patient care database. Neurology 1999: 52: A166.
14. McGuire V, Longstreth WT Jr, Koepsell TD, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 1996: 47: 571-573.
15. Elian M, Dean G. Motor neuron disease and multiple sclerosis among immigrants to England from the Indian subcontinent, the Caribbean, and east and west Africa. J Neurol Neurosurg Psychiatry 1993: 56: 454-457.
16. Kahana E, Zilber N. Changes in the incidence of amyotrophic lateral sclerosis in Israel. Arch Neurol 1984: 41: 157-160.
17. Jokelainen M. Amyotrophic lateral sclerosis in Finland. I. An epidemiologic study. Acta Neurol Scand 1977: 56: 185-193.
18. Tysnes OB, Vollset SE, Aarli JA. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand 1991: 83: 280-285.
19. Gunnarsson LG, Lygner PE, Veiga-Cabo J, de Pedro-Cuesta J. An epidemic-like cluster of motor neuron disease in a Swedish county during the period 1973-84. Neuroepidemiology 1996: 15: 142-152.
20. Kurland LTMD. Epidemiologic investigations of amyotrophic lateral sclerosis. 1. Preliminary report on geographical distribution, with special reference to the Mariana Islands, including ethnical and pathological observations. Neurology 1954: 4: 438-448.
21. Oyanagi K, Wada M. Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: an update. J Neurol 1999: 246: 1119-27.
22. McGeer PL, Schwab C, McGeer EG, Haddock RL, Steele JC. Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Neurology 1997: 49: 400-409.
23. Wiederholt WC. Neuroepidemiologic research initiatives on Guam: past and present. Neuroepidemiology 1999: 18: 279-291.
24. Zhang ZX, Anderson DW, Mantel N, Roman GC. Motor neuron disease on Guam: geographic and familial occurrence, 1956-85. Acta Neurol Scand 1996: 94: 51-59.
25. Yase Y, Matsumoto N, Yoshimasu F, Handa Y, Kumamoto T. Motor neuron disease in the Kii peninsula. Japan Proc Aust Assoc Neurol 1968: 5: 335-339.
26. Handa YYM, Yata Y. Epidemiological and geomedical studies on amyotrophic lateral sclerosis. Dis Nerv Syst 1963: 24: 155-159.
27. Gajdusek DC, Salazar AM. Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology 1982: 32: 107-126.
28. Kiloh LG, Lethlean AK, Morgan G, Cawte JE, Harris M. An endemic neurological disorder in tribal Australian aborigines. J Neurol Neurosurg Psychiatry 1980: 43: 661-668.
29. Chen X, Xia Y, Gresham LS et al. ApoE and CYP2D6 polymorphism with and without parkinsonism-dementia complex in the people of Chamorro, Guam. Neurology 1996: 47: 779-784.
30. Melmed C, Krieger C. A cluster of amyotrophic lateral sclerosis. Arch Neurol 1982: 39: 595-596.
31. Hyser CL, Kissel JT, Mendell JR. Three cases of amyotrophic lateral sclerosis in a common occupational environment. J Neurol 1987: 234: 443-444.
32. Hochberg FH, Bryan JA, Whelan MA. Clustering of amyotrophic lateral sclerosis (Letter). Lancet 1974: 1: 34.
33. Kilness AW, Hichherg FH. Amyotrophic lateral sclerosis in a high selenium environment. JAMA 1977: 237: 2843-2844.
34. Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994: 145: 1271-1279.
35. Sanders M. Clustering of amyotrophic lateral sclerosis. JAMA 1980: 244: 435.
36. Sienko DG, Davis JP, Taylor JA, Brooks BR. Amyotrophic lateral sclerosis. A case-control study following detection of a cluster in a small Wisconsin community. Arch Neurol 1990: 47: 38-41.
37. Taylor JA, Davis JP. Evidence for clustering of amyotrophic lateral sclerosis in Wisconsin. J Clin Epidemiol 1989: 42: 569-575.
38. Reed DM, Torres JM, Brody JA. Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945-1972. II. Familial and genetic studies. Am J Epidemiol 1975: 101: 302-310.
39. Cornblath DR, Kurland LT, Boylan KB, Morrison L, Radhakrishnan K, Montgomery M. Conjugal amyotrophic lateral sclerosis: report of a young married couple. Neurology 1993: 43: 2378-2380.
40. Maloo JC, Radhakrishnan K, Poddar SK, Thacker AK. Conjugal motor neurone disease. J Assoc Physicians India 1987: 35: 303-304.
41. Chad D, Mitsumoto H, Adelman LS, Bradley WG, Munsat TL, Zieper I. Conjugal motor neuron disease. Neurology 1982: 32: 306-307.
42. Paolino E, Granieri E, Tola MR, Rosati G. Conjugal amyotrophic lateral sclerosis. Ann Neurol 1983: 14: 699.
43. Bailey-Wilson JE, Plato CC, Elston RC, Garruto RM. Potential role of an additive genetic component in the cause of amyotrophic lateral sclerosis and parkinsonism-dementia in the western Pacific. Am J Med Genet 1993: 45: 68-76.
44. Ahlskog JE, Waring SC, Kurland LT et al. Guamanian neurodegenerative disease: investigation of the calcium metabolism/heavy metal hypothesis. Neurology 1995: 45: 1340-1344.
45. Sacks O. The Island of the Colour-Blind and Cycad Island. London: Picador, 1996.
46. Kisby GE, Ellison M, Spencer PS. Content of the neurotoxins cycasin (methylazoxymethanol beta-D-glucoside) and BMAA (beta-N-methylamino-1-alanine) in cycad flour prepared by Guam Chamorros. Neurology 1992: 42: 1336-1340.
47. Spencer PS, Kisby GE, Ludolph AC. Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology 1991: 41: 62-66.
48. Duncan MW. Beta-Methylamino-L-Alanine (BMAA) and amyotrophic lateral sclerosis- parkinsonism dementia of the western Pacific. Ann N Y Acad Sci 1992: 648: 161-168.
49. Esclaire F, Kisby G, Spencer P, Milne J, Lesort M, Hugon J. The Guam cycad toxin methylazoxymethanol damages neuronal DNA and modulates tau mRNA expression and excitotoxicity. Exp Neurol 1999: 155: 11-21.
50. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol 1985: 232: 295-300.
51. Giraud P, Kopp N, Lina B, Chazot G. Amyotrophic lateral sclerosis: a role for enteroviruses? Rev Neurol (Paris) 2000: 156: 352-356.
52. Karpati G, Dalakas MC. Viral hide-and-seek in sporadic ALS: a new challenge. Neurology 2000: 54: 6-7.
53. Berger MM, Kopp N, Vital C, Redl B, Aymard M, Lina B. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000: 54: 20-25.
54. Woodall CJ, Riding MH, Graham DI, Clements GB. Sequences specific for enterovirus detected in spinal cord from patients with motor neurone disease. BMJ 1994: 308: 1541-1543.
55. Muir P, Nicholson F, Spencer GTI et al. Enterovirus infection of the central nervous system of humans: lack of association with chronic neurological disease. J Gen Virol 1996: 77: 1469-1476.
56. Swanson NR, Fox SA, Mastaglia FL. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromuscul Disord 1995: 5: 457-465.
57. Walker MP Schlaberg R, Hays AP, Bowser R, Lipkin WI. Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. Ann Neurol 2001: 49: 249-253.
58. Corcia P, Mayeux-Portas V, Khoris J et al. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 2002: 51: 243-246.
59. Veldink JH, van den Berg LH, Cobben JM et al. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology 2001: 56: 749-752.
60. Parboosingh JS, Meininger V, McKenna-Yasek D, Brown RH Jr, Rouleau GA. Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. Arch Neurol 1999: 56: 710-712.
61. Orrell RW, Habgood JJ, de Belleroche JS, Lane RJ. The relationship of spinal muscular atrophy to motor neuron disease: investigation of SMN and NAIP gene deletions in sporadic and familial ALS. J Neurol Sci 1997: 145: 55-61.
62. Moulard B, Salachas F, Chassande B et al. Association between centromeric deletions of the SMN gene and sporadic adult-onset lower motor neuron disease. Ann Neurol 1998: 43: 640-644.
63. Jackson M, Morrison KE, Al-Chalabi A, Bakker M, Leigh PN. Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. Ann Neurol 1996: 39: 796-800.
64. Garofalo O, Figlewicz DA, Leigh PN et al. Androgen receptor gene polymorphisms in amyotrophic lateral sclerosis. Neuromuscul Disord 1993: 3: 195-199.
65. Parboosingh JS, Figlewicz DA, Krizus A et al. Spinobulbar muscular atrophy can mimic ALS. the importance of genetic testing in male patients with atypical ALS. Neurology 1997: 49: 568-572.
66. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997: 41: 210-221.
67. de Belleroche J, Orrell R, King A. Familial amyotrophic lateral scleorosis/motor neurone disease (FALS): a review of current developments. J Med Genet 1995: 32: 841-847.
68. Chio A, Brignolio F, Meineri P, Schiffer D. Phenotypic and genotypic heterogeneity of dominantly inherited amyotrophic lateral sclerosis. Acta Neurol Scand 1987: 75: 277-282.
69. Husquinet H, Franck G. Hereditary amyotrophic lateral sclerosis transmitted for five generations. Clin Genet 1980: 18: 109-115.
70. Suthers G, Laing N, Wilton S, Dorosz S, Waddy H. Sporadic motoneuron disease due to familial SOD1 mutation with low penetrance. Lancet 1994: 344: 1773.
71. Cudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH Jr. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol 1998: 43: 703-710.
72. Siddique T, Figlewicz DA, Pericak-Vance MA et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 1991: 324: 1381-1384.
73. Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993: 362: 59-62.
74. Orrell RW. Amyotrophic lateral sclerosis: copper/zinc superoxide dismutase (SOD1) gene mutations. Neuromuscul Disord 2000: 10: 63-68.
75. Andersen PM, Nilsson P, Ala-Hurula V et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet 1995: 10: 61-66.
76. Robberecht W, Aguirre T, Van den Bosch L, Tilkin P, Cassiman JJ, Matthijs G. D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. Neurology 1996: 47: 1336-1339.
77. Hand CK, Mayeux-Portas V, Khoris J et al. Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Ann Neurol 2001: 49:267-271.
78. Pramatarova A, Figlewicz DA, Krizus A et al. Identification of new mutations in the Cu/Zn superoxide dismutase gene of patients with familial amyotrophic lateral sclerosis. Am J Hum Genet 1995: 56: 592-596.
79. Orrell RW, Habgood JJ, Gardiner I et al. Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Neurology 1997: 48: 746-751.
80. Orrell RW, Habgood JJ, Malaspina A et al. Clinical characteristics of SOD1 gene mutations in UK families with ALS. J Neurol Sci 1999: 169: 56-60.
81. Andersen PM, Nilsson P, Keranen ML et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997: 120: 1723-1737.
82. Jones CT, Swingler RJ, Simpson SA, Brock DJ. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995: 32: 290-292.
83. Aguirre T, Matthijs G, Robberecht W, Tilkin P, Cassiman JJ. Mutational analysis of the Cu/Zn superoxide dismutase gene in 23 familial and 69 sporadic cases of amyotrophic lateral sclerosis in Belgium. Eur J Hum Genet 1999: 7: 599-602.
84. Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Neurology 1997: 48: 55-57.
85. Andersen PM, Forsgren L, Binzer M et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996: 119: 1153-1172.
86. Jackson M, Al-Chalabi A, Enayat ZE, Chioza B, Leigh PN, Morrison KE. Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 cases and identification of a novel insertion mutation. Ann Neurol 1997: 42: 803-807.
87. Radunovic A, Leigh PN. Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry 1996: 61: 565-572.
88. Hayward C, Swingler RJ, Simpson SA, Brock DJ. A specific superoxide dismutase mutation is on the same genetic background in sporadic and familial cases of amyotrophic lateral sclerosis. Am J Hum Genet 1996: 59: 1165-1167.
89. Mezei M, Andersen PM, Stewart H, Weber M, Eisen A. Motor system abnormalities in heterozygous relatives of a D90A homozygous CuZn-SOD ALS patient of Finnish extraction. J Neurol Sci 1999: 169: 49-55.
90. Khoris J, Moulard B, Briolotti V et al. Coexistence of dominant and recessive familial amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase mutation within the same country. Eur J Neurol 2000: 7: 207-211.
91. Morita M, Aoki M, Abe K et al. A novel two-base mutation in the Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis in Japan. Neurosci Lett 1996: 205: 79-82.
92. Sjalander A, Beckman G, Deng HX, Iqbal Z, Tainer JA, Siddique T. The D90A mutation results in a polymorphism of Cu,Zn superoxide dismutase that is prevalent in northern Sweden and Finland. Hum Mol Genet 1995: 4: 1105-1108.
93. Harris H, Hopkinson DA, Robson EB. The incidence of rare alleles determining electrophoretic variants: data on 43 enzyme loci in man. Ann Hum Genet 1974: 37: 237-253.
94. Al-Chalabi A, Andersen PM, Chioza B et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet 1998: 7: 2045-2050.
95. Camu W, Khoris J, Moulard B et al. Genetics of familial ALS and consequences for diagnosis. French ALS Research Group. J Neurol Sci 1999: 165: S21-S26.
96. Orrell RW, King AW, Hilton DA, Campbell MJ, Lane RJ, de Belleroche JS. Familial amyotrophic lateral sclerosis with a point mutation of SOD-1: intrafamilial heterogeneity of disease duration associated with neurofibrillary tangles. J Neurol Neurosurg Psychiatry 1995: 59: 266-270.
97. Ikeda M, Abe K, Aoki M et al. Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene. Neurology 1995: 45: 2038-2042.
98. Deng HX, Tainer JA, Mitsumoto H et al. Two novel SOD1 mutations in patients with familial amyotrophic lateral sclerosis. Hum Mol Genet 1995: 4: 1113-1116.
99. Jones CT, Swingler RJ, Brock DJ. Identification of a novel SOD1 mutation in an apparently sporadic amyotrophic lateral sclerosis patient and the detection of Ile113Thr in three others. Hum Mol Genet 1994: 3: 649-650.
100. Rosen DR, Bowling AC, Patterson D et al. A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis. Hum Mol Genet 1994: 3: 981-987.
101. Aoki M, Abe K, Houi K et al. Variance of age at onset in a Japanese family with amyotrophic lateral sclerosis associated with a novel Cu/Zn superoxide dismutase mutation. Ann Neurol 1995: 37: 676-679.
102. Aoki M, Abe K, Itoyama Y. Molecular analyses of the Cu/Zn superoxide dismutase gene in patients with familial amyotrophic lateral sclerosis (ALS) in Japan. Cell Mol Neurobiol 1998: 18: 639-647.
103. Ince PG, Tornkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase. molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropathol Exp Neurol 1998: 57: 895-904.
104. Ratovitski T, Corson LB, Strain J et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum Mol Genet 1999: 8: 1451-1460.
105. Reaume AG, Elliott JL, Hoffman EK et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996: 13: 43-47.
106. Chan PH, Chu L, Chen SF, Carlson EJ, Epstein CJ. Reduced neurotoxicity in transgenic mice overexpressing human copper-zinc-superoxide dismutase. Stroke 1990: 21: III80-82.
107. Bruijn LI, Houseweart MK, Kato S et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998: 281: 1851-1854.
108. Kunst CB, Mezey E, Brownstein MJ, Patterson D. Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat Genet 1997: 15: 91-94.
109. Julien JP, Couillard-Despres S, Meier J. Transgenic mice in the study of ALS. the role of neurofilaments. Brain Pathol 1998: 8: 759-769.
110. Williamson TL, Bruijn LI, Zhu Q et al. Absence of neuro-filaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1998: 95: 9631-9636.
111. Couillard-Despres S, Zhu Q, Wong PC, Price DL, Cleveland DW, Julien JP. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 1998: 95: 9626-9630.
112. Trotti D, Rolfs A, Danbolt NC, Brown RH Jr, Hediger MA. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999: 2: 427-33.
113. Kruman II, Pedersen WA, Springer JE, Mattson MP. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol 1999: 160: 28-39.
114. Roy J, Minotti S, Dong L, Figlewicz DA, Durham HD. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J Neurosci 1998: 18: 9673-9684.
115. Jaarsma D, Rognoni F, van Duijn W, Verspaget HW, Haasdijk ED, Holstege JC. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol (Berl) 2001: 102: 293-305.
116. Ferri A, Gabbianelli R, Casciati A, Ceisi F, Rotilio G, Carri MT. Oxidative inactivation of calcineurin by Cu,Zn superoxide dismutase G93A, a mutant typical of familial amyotrophic lateral sclerosis. J Neurochem 2001: 79: 531-538.
117. Ferri A, Gabbianelli R, Casciati A, Paolucci E, Rotilio G, Carri MT. Calcineurin activity is regulated both by redox compounds and by mutant familial amyotrophic lateral sclerosis-superoxide dismutase. J Neurochem 2000: 75: 606-613.
118. Shaw CE, Enayat ZE, Powell JF et al. Familial amyotrophic lateral sclerosis. Molecular pathology of a patient with a SOD1 mutation. Neurology 1997: 49: 1612-1616.
119. Jones CT, Shaw PJ, Chari G, Brock DJ. Identification of a novel exon 4 SOD1 mutation in a sporadic amyotrophic lateral sclerosis patient. Mol Cell Probes 1994: 8: 329-330.
120. Kokubo Y, Kuzuhara S, Narita Y et al. Accumulation of neurofilaments and SOD1-immunoreactive products in a patient with familial amyotrophic lateral sclerosis with I113T SOD1 mutation. Arch Neurol 1999: 56: 1506-1508.
121. Rouleau GA, Clark AW, Rooke K et al. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol 1996: 39: 128-131.
122. Kato S, Takikawa M, Nakashima K et al. New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph Eateral Scler Other Motor Neuron Disord 2000: 1: 163-184.
123. Kato S, Sumi-Akamaru H, Fujimura H et al. Copper chaperone for superoxide dismutase co-aggregates with superoxide dismutase 1 (SOD1) in neuronal Lewy body-like hyaline inclusions: an immunohistochemical study on familial amyotrophic lateral sclerosis with SOD1 gene mutation. Acta Neuropathol (Berl) 2001: 102: 233-238.
124. Hentati A, Bejaoui K, Pericak-Vance MA et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet 1994: 7: 425-428.
125. Hadano S, Yanagisawa Y, Skaug J et al. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. Genomics 2001: 71: 200-213.
126. Hadano S, Hand CK, Osuga H et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001: 29: 166-173.
127. Yang Y, Hentati A, Deng HX et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001: 29: 160-165.
128. Rabin BA, Griffin JW, Grain BJ, Scavina M, Chance PF, Cornblath DR. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain 1999: 122: 1539-1550.
129. Hentati AOK, Pericak-Vance MA, Ahmad A et al. Linkage of a common locus for recessive amyotrophic lateral sclerosis. Am J Hum Genet 1997: 61: A279.
130. Cox PR, Zoghbi HY. Sequencing, expression analysis, and mapping of three unique human tropomodulin genes and their mouse orthologs. Genomics 2000: 63: 97-107.
131. Hand CK, Khoris J, Salachas F et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2001: 70: 1.
132. Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994: 55: 1159-1165.
133. Stanford PM, Halliday GM, Brooks WS et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain 2000: 123: 880-893.
134. Bird TD, Nochlin D, Poorkaj P et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 1999: 122: 741-756.
135. Spillantini MG, Goedert M. Tau mutations in familial frontotemporal dementia. Brain 2000: 123: 857-859.
136. Bugiani O, Murrell JR, Giaccone G et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999: 58: 667-677.
137. Pastor P, Pastor E, Carnero C et al. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Ann Neurol 2001: 49: 263-267.
138. Hutton M, Lendon CL, Rizzu P et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998: 393: 702-705.
139. Stevens M, van Duijn CM, Kamphorst W et al. Familial aggregation in frontotemporal dementia. Neurology 1998: 50: 1541-1545.
140. Houlden H, Baker M, Adamson J et al. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. Ann Neurol 1999: 46: 243-248.
141. Rizzu P, Van Swieten JC, Joosse M et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 1999: 64: 414-421.
142. Poorkaj P, Grossman M, Steinbart E et al. Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol 2001: 58: 383-387.
143. Heutink P. Untangling tau-related dementia. Hum Mol Genet 2000: 9: 979-986.
144. Ishihara T, Hong M, Zhang B et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999: 24: 751-762.
145. Probst A, Gotz J, Wiederhold KH et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein [In Process Citation]. Acta Neuropathol (Berl) 2000: 99: 469-481.
146. Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias. Neuron 1998: 21: 955-958.
147. Caparros-Lefebvre D, Sergeant N, Lees A et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002: 125: 801-811.
148. Schmidt ML, Zhukareva V, Perl DP et al. Spinal cord neurofibrillary pathology in Alzheimer disease and Guam Parkinsonism-dementia complex. J Neuropathol Exp Neurol 2001: 60: 1075-1086.
149. Poorkaj P, Tsuang D, Wijsman E et al. TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of Guam. Arch Neurol 2001: 58: 1871-1878.
150. Przedborski S, Dhawan V, Donaldson DM et al. Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations. Neurology 1996: 47: 1546-1551.
151. Kikugawa K, Nakano R, Inuzuka T et al. A missense mutation in the SOD1 gene in patients with amyotrophic lateral sclerosis from the Kii Peninsula and its vicinity, Japan. Neurogenetics 1997: 1: 113-115.
152. Figlewicz DA, Garruto RM, Krizus A, Yanagihara R, Rouleau GA. The Cu/Zn superoxide dismutase gene in ALS and parkinsonism-dementia of Guam. Neuroreport 1994: 5: 557-560.
153. Clark LN, Poorkaj P, Wszolek Z et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 1998: 95: 13103-13107.
154. Dumanchin C, Camuzat A, Campion D et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet 1998: 7: 1825-1829.
155. Hosler BA, Siddique T, Sapp PC et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000: 284: 1664-1669.
156. Ludolph AC, Langen KJ, Regard M et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992: 85: 81-89.
157. Rossor MN, Revesz T, Lantos PL, Warrington EK. Semantic dementia with ubiquitin-positive tau-negative inclusion bodies. Brain 2000: 123: 267-276.
158. Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology 1994: 44: 1872-1877.
159. Deapen DM, Henderson BE. A case-control study of amyotrophic lateral sclerosis. Am J Epidemiol 1986: 123: 790-799.
160. Gunnarsson LG, Bodin L, Soderfeldt B, Axelson O. A case-control study of motor neurone disease: its relation to heritability, and occupational exposures, particularly to solvents. Br J Ind Med 1992: 49: 791-798.
161. Majoor-Krakauer D, Hofman A, Galjaard H, Johnson WG, Rowland LP, Ottman R. Increased familial aggregation of dementia and parkinsonism in amyotrophic lateral sclerosis. Clin Genet 2002: 62.
162. Vance JM, Pericak-Vance MA, Bowman MH et al. Chorea-acanthocytosis: a report of three new families and implications for genetic counselling. Am J Med Genet 1987: 28: 403-410.
163. Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology 1985: 35: 366-370.
164. Rubio JP, Danek A, Stone C et al. Chorea-acanthocytosis: genetic linkage to chromosome 9q21. Am J Hum Genet 1997: 61: 899-908.
165. Brait K, Fahn S, Schwarz GA. Sporadic and familial parkinsonism and motor neuron disease. Neurology 1973: 23: 990-1002.
166. Alter M, Schaumann B. A family with amyotrophic lateral sclerosis and parkinsonism. J Neurol 1976: 212: 281-284.
167. van Bogaert L, Rademecker M. Scleroses laterales amyotrophiques typiques et paralysies agitante hereditaire dans une meme famille avec une forme de passage possible entre les deux affections. Neurology 1954: 127: 185-203.
168. Biemond S, Beck W. Neural muscle atrophy with degeneration of the substamtia nigra. Confinia Neurol 1955: 15: 142-153.
169. Ziegler DK, Schimke RN, Kepes JJ, Rose DL, Klinkerfuss G. Late onset ataxia, rigidity, and peripheral neuropathy. A familial syndrome with variable therapeutic response to levodopa. Arch Neurol 1972: 27: 52-66.
170. Tranchant C, Dugay MH, Mohr M, Wasser P, Warter JM. Familial motor neuron disease with Lewy body-like inclusions in the substantia nigra, the subthalamic nucleus, and the globus pallidus. J Neurol Sci 1992: 108: 18-23.
171. Staal A, Went LN. Juvenile amyotrophic lateral sclerosis-dementia complex in a Dutch family. Neurology 1968: 18: 800-806.
172. Otero Siliceo E, Arriada-Mendicoa N, Balderrama J. Juvenile familial amyotrophic lateral sclerosis: four cases with long survival. Dev Med Child Neurol 1998: 40: 425-428.
173. Dazzi P, Finizio FS. Familial amyotrophic lateral sclerosis. G Psychiatr Neuropathol 1969: 97: 299-337.
174. Finlayson MH, Martin JB. Cerebral lesions in familial amyotrophic lateral sclerosis and dementia. Acta Neuropathol (Berl) 1973: 26: 237-246.
175. Pinsky L, Finlayson MH, Libman I, Scott BH. Familial amyotrophic lateral sclerosis with dementia: a second canadian family. Clin Genet 1975: 7: 186-191.
176. Robertson E. Progressive bulbar palsy showing heredofamilial incidence and intellectual impairment. Arch Neurol 1953: 69: 197-207.
177. Gunnarsson LG, Dahlbom K, Strandman E. Motor neuron disease and dementia reported among 13 members of a single family Acta Neurol Scand 1991: 84: 429-433.
178. Rosenberg RN. Amyotrophy in multisystem genetic diseases. Adv Neurol 1982: 36: 149-158.
179. Bots GT, Staal A. Amyotrophic lateral sclerosis-dementia complex, neuroaxonal dystrophy, and Hallervorden-Spatz disease. Neurology 1973: 23: 35-39.
180. Morrison BM, Morrison JH, Gordon JW. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis. J Exp Zool 1998: 282: 32-47.
181. Julien JP. Neurofilament functions in health and disease. Curr Opin Neurobiol 1999: 9: 554-560.
182. Corbo M, Hays AR Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol 1992: 51: 531-537.
183. Beaulieu JM, Nguyen MD, Julien JP. Late onset death of motor neurons in mice overexpressing wild-type peripherin. J Cell Biol 1999: 147: 531-544.
184. Robertson J, Beaulieu JM, Doroudchi MM, Durham HD, Julien JP, Mushynski WE. Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. J Cell Biol 2001: 155: 217-226.
185. Al-Chalabi A, Andersen PM, Nilsson P et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999: 8: 157-164.
186. Cleveland DW. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 1999: 24: 515-520.
187. Figlewicz DA, Krizus A, Martinoli MG et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994: 3: 1757-1761.
188. Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994: 264: 1772-1775.
189. Julien JP, Grosveld F, Yazdanbaksh K, Flavell D, Meijer D, Mushynski W. The structure of a human neurofilament gene (NF-L): a unique exon-intron organization in the intermediate filament gene family. Biochim Biophys Acta 1987: 909: 10-20.
190. Tomkins J, Usher P, Slade JY et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 1998: 9: 3967-3970.
191. Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993: 73: 23-33.
192. Collard JF Cote F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995: 375: 61-64.
193. Wong NK, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J Neuropathol Exp Neurol 2000: 59: 972-982.
194. Beaulieu JM, Jacomy H, Julien JP. Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit. J Neurosci 2000: 20: 5321-5328.
195. Mersiyanova IV, Perepelov AV, Polyakov AV et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000: 67: 37-46.
196. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994: 13: 975-988.
197. Nguyen MD, Lariviere RC, Julien JP. Reduction of axonal caliber does not alleviate motor neuron disease caused by mutant superoxide dismutase 1. Proc Natl Acad Sci USA 2000: 97: 12306-12311.
198. Kong J, Xu Z. Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis. Neurosci Lett 2000: 281: 72-74.
199. Couillard-Despres S, Meier J, Julien JP. Extra axonal neurofilaments do not exacerbate disease caused by mutant Cu,Zn superoxide dismutase. Neurobiol Dis 2000: 7: 462-470.
200. Nicholson SJ, Witherden AS, Hafezparast M, Martin JE, Fisher EM. Mice, the motor system, and human motor neuron pathology. Mamm Genome 2000: 11: 1041-1052.
201. Julien JP. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 2001: 104: 581-591.
202. Appel SH, Beers D, Siklos L, Engelhardt JI, Mosier DR. Calcium. the Darth Vader of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001: 2: S47-S54.
203. Beers DR, Ho BK, Siklos L et al. Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J Neurochem 2001: 79: 499-509.
204. Lin CL, Bristol LA, Jin L et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998: 20: 589-602.
205. Rothstein JD, Tsai G, Kuncl RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990: 28: 18-25.
206. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992: 326: 1464-1468.
207. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 1996: 16: 406Y-4079.
208. Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999: 46: 806-815.
209. Esclaire F, Terro F, Yardin C, Hugon J. Neuronal apoptosis is associated with a decrease in tau mRNA expression. Neuroreport 1998: 9: 1173-1177.
210. Spencer PS, Nunn PB, Hugon J et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987: 237: 517-522.
211. Couratier P, Sindou P, Tabaraud F, Diop AG, Spencer PS, Hugon J. Modulation of tau neuronal expression induced by NMDA, non-NMDA and metabotropic glutamate receptor agonists. Neurodegeneration 1995: 4: 33-41.
212. Esclaire F, Lesort M, Blanchard C, Hugon J. Glutamate toxicity enhances tau gene expression in neuronal cultures. J Neurosci Res 1997: 49: 309-318.
213. Sindou P, Couratier P, Barthe D, Hugon J. A dose-dependent increase of Tau immunostaining is produced by glutamate toxicity in primary neuronal cultures. Brain Res 1992: 572: 242-246.
214. Sindou P, Lesort M, Couratier P, Yardin C, Esclaire F, Hugon J. Glutamate increases tau phosphorylation in primary neuronal cultures from fetal rat cerebral cortex. Brain Res 1994: 646: 124-128.
215. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995: 38: 73-84.
216. Aoki M, Lin CL, Rothstein JD et al. Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. Ann Neurol 1998: 43: 645-653.
217. Jackson M, Steers G, Leigh PN, Morrison KE. Polymorphisms in the glutamate transporter gene EAAT2 in European ALS patients. J Neurol 1999: 246: 1140-1144.
218. Meyer T, Munch C, Volkel H, Booms P, Ludolph AC. The EAAT2 (GLT-1) gene in motor neuron disease: absence of mutations in amyotrophic lateral sclerosis and a point mutation in patients with hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry 1998: 65: 594-596.
219. Mui S, Rebeck GW, McKenna-Yasek D, Hyman BT, Brown RH Jr. Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol 1995: 38: 460-463.
220. Al-Chalabi A, Enayat ZE, Bakker MC et al. Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Lancet 1996: 347: 159-160.
221. Warwick Daw E, Payami H, Nemens EJ et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 2000: 66: 196-204.
222. Drory VE, Birnbaum M, Korczyn AD, Chapman J. Association of APOE varepsilon4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci 2001: 190: 17-20.
223. Strittmatter WJ, Saunders AM, Schmechel D et al. High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993: 90: 1977-1981.
224. Pedersen WA, Chan SL, Mattson MP. A mechanism for the neuroprotective effect of apolipoprotein E. isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J Neurochem 2000: 74: 1426-1433.
225. Bachus R, Bader S, Gessner R, Ludolph AC. Lack of association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Ann Neurol 1997: 41: 417.
226. Smith RG, Haverkamp LJ, Case S, Appel V, Appel SH. Apolipoprotein E epsilon 4 in bulbar-onset motor neuron disease. Lancet 1996: 348: 334-335.
227. Waring SC, O'Brien PC, Kurland LT et al. Apolipoprotein E allele in Chamorros with arnyotrophic lateral sclerosis/parkinsonism-dementia complex. Lancet 1994: 343: 611.
228. Ono S, Imai T, Igarashi A, Shimizu N, Nakagawa H, Hu J. Decrease in the ciliary neurotrophic factor of the spinal cord in amyotrophic lateral sclerosis. Eur Neurol 1999: 42: 163-168.
229. Masu Y, Wolf E, Holtmann B, Sendtner M, Brem G, Thoenen H. Disruption of the CNTF gene results in motor neuron degeneration. Nature 1993: 365: 27-32.
230. Orrell RW, King AW, Lane RJ, de Belleroche JS. Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis. J Neurol Sci 1995: 132: 126-128.
231. Takahashi R, Yokoji H, Misawa H, Hayashi M, Hu J, Deguchi T. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nat Genet 1994: 7: 79-84.
232. Smith CA, Gough AC, Leigh PN et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease [published erratum appears in Lancet 1992 July 4; 340 (8810): 64] [see comments]. Lancet 1992: 339: 1375-1377.
233. James CM, Daniels J, Wiles CM, Owen MJ. Debrisoquine hydroxylase gene polymorphism in motor neuron disease. Neurodegeneration 1994: 3: 149-152.
234. Siddons MA, Pickering-Brown SM, Mann DM, Owen F, Cooper PN. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Neurosci Lett 1996: 208: 65-68.
235. Kisby GE, Milne J, Sweatt C. Evidence of reduced DNA repair in amyotrophic lateral sclerosis brain tissue. Neuroreport 1997: 8: 1337-1340.
236. Olkowski ZL. Mutant AP endonuclease in patients with amyotrophic lateral sclerosis. Neuroreport 1998: 9: 239-242.
237. Hayward C, Colville S, Swingler RJ, Brock DJ. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 1999: 52: 1899-1901.
238. Tomkins J, Dempster S, Banner SJ, Cookson MR, Shaw PJ. Screening of AP endonuclease as a candidate gene for amyotrophic lateral sclerosis (ALS). Neuroreport 2000: 11: 1695-1697.
239. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000: 23: 298-304.
240. Wiedemann FR, Winkler K, Kuznetsov AV et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998: 156: 65-72.
241. Pedersen WA, Fu W, Keller JN et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998: 44: 819-824.
242. Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 1995: 38: 691-695.
243. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993: 61: 2322-2325.
244. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998: 18: 3241-3250.
245. Wong PC, Pardo CA, Borchelt DR et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995: 14: 1105-1116.
246. Vielhaber S, Kunz D, Winkler K et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 2000: 123: 1339-1348.
247. Comi GP, Bordoni A, Salani S et al. Cytochrome-c oxidase subunit-I microdeletion in a patient with motor neuron disease. Ann Neurol 1998: 43: 110-116.
248. Van Landeghem GF, Tabatabaie P, Beckman G, Beckman L, Andersen PM. Manganese-containing superoxide dismutase signal sequence polymorphism associated with sporadic motor neuron disease. Eur J Neurol 1999: 6: 639-644.
249. Melov S, Schneider JA, Day BJ et al. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet 1998: 18: 159-163.
250. Lebowitz MS, Pedersen PL. Protein inhibitor of mitochondrial ATP synthase: relationship of inhibitor structure to pH-dependent regulation. Arch Biochem Biophys 1996: 330: 342-354.
251. Li Y, Copin JC, Reola LF et al. Reduced mitochondrial manganese-superoxide dismutase activity exacerbates glutamate toxicity in cultured mouse cortical neurons. Brain Res 1998: 814: 164-170.
252. Andreassen OA, Ferrante RJ, Klivenyi P et al. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Ann Neurol 2000: 47: 447-455.
253. Wong PC, Waggoner D, Subramaniam JR et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA 2000: 97: 2886-2891.
254. Orru S, Mascia V, Casula M et al. Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis. Neuromuscul Disord 1999: 9: 593-597.
255. Vukosavic S, Dubois-Dauphin M, Romero N, Przedborski S. Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999: 73: 2460-2468.
256. Jaarsma D, Holstege JC, Troost D et al. Induction of c-Jun immunoreactivity in spinal cord and brainstem neurons in a transgenic mouse model for amyotrophic lateral sclerosis. Neurosci Lett 1996: 219: 179-182.
257. Virgo L, de Belleroche J. Induction of the immediate early gene c-jun in human spinal cord in amyotrophic lateral sclerosis with concomitant loss of NMDA receptor NR-1 and glycine transporter mRNA. Brain Res 1995: 676: 196-204.
258. Rowland LP. Neuromuscular disorder associated with malignant neoplastic disease. J Chron Dis 1963: 16: 777-795.
259. Louis ED, Hanley AE, Brannagan TH et al. Motor neuron disease, lymphoproliferative disease, and bone marrow biopsy. Muscle Nerve 1996: 19: 1334-1337.
260. Gordon PH, Rowland LP, Younger DS et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology 1997: 48: 1671-1678.
261. Gnarra JR, Otani H, Wang MG, McBride OW, Sharon M, Leonard WJ. Human interleukin 2 receptor beta-chain gene. chromosomal localization and identification of 5′ regulatory sequences. Proc Natl Acad Sci USA 1990: 87: 3440-3444.
262. Meyer MA, Potter NT. Sporadic ALS and chromosome 22: evidence for a possible neurofilament gene defect. Muscle Nerve 1995: 18: 536-539.
263. Plato CC, Rucknagel DL, Kurland LT. Blood group investigations on the Carolinians and Chamorros of Saipan. Am J Phys Anthropol 1966: 24: 147-154.
264. Beckman L, Cedergren B, Collinder E, Rasmuson M. Population studies in northern Sweden. III. Variations of ABO and Rh blood group gene frequencies in time and space. Hereditas 1972: 72: 183-200.
265. Meyer MA, Poduslo JF, Kurland LT. Structural similarities between ganglioside GM1 and antigens of the P2 phenotype. Ann Neurol 1989: 26: 693-694.
266. Giess R, Beck M, Goetz R, Nitsch RM, Toyka KV, Sendtner M. Potential role of LIF as a modifier gene in the pathogenesis of amyotrophic lateral sclerosis. Neurology 2000: 54: 1003-1005.
267. Oosthuyse B, Moons L, Storkebaum E et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001: 28: 131-138.
268. Newbery HJ, Abbott CM. Of mice, men and motor neurons. Trends Genet 2001: 17: S2-S6.
269. Anderson FH, Richardson EP Jr, Okazaki H, Brody JA. Neurofibrillary degeneration on Guam: frequency in Chamorros and non Chamorros with no known neurological disease. Brain 1979: 102: 65-77.
270. Buee-Scherrer V, Buee L, Hof PR et al. Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. Am J Pathol 1995: 146: 924-932.
271. Slooter AJ, van Duijn CM. Genetic epidemiology of Alzheimer disease. Epidemiol Rev 1997: 19: 107-119.
272. Trojanowski JQ, Lee VM. Fatal attractions of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann N Y Acad Sci 2000: 924: 62-67.